Is Twist Bioscience (NASDAQ:TWST) a buy in 2026?
Hold. Twist Bioscience is a wait-and-watch at today's price, not a fresh buy.
Twist is winning synthetic biology's platform war but burning cash near a 52-week high with 30% short interest — patience required.
Where TWST is headed
Twist Bioscience sits at one of biotech's most interesting crossroads: it owns the most advanced silicon-based DNA synthesis platform on the planet, and it's slowly converting that technological superiority into commercial traction across NGS, biopharma, and — eventually — DNA data storage. By late 2027, Twist should be approaching $400M in annual revenue, with gross margins pushing toward 55-58% as manufacturing scale economics finally kick in from its Factory of the Future in Wilsonville, Oregon. The NGS tools business, which has been quietly compounding through panel expansion and methylation detection kits, could represent 40%+ of revenue as liquid biopsy and minimal residual disease testing proliferate.
Read the full Compass Direction on TWST
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full TWST analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Twist Bioscience (NASDAQ:TWST) a buy in 2026?
Hold. Twist Bioscience is a wait-and-watch at today's price, not a fresh buy. Twist is winning synthetic biology's platform war but burning cash near a 52-week high with 30% short interest — patience required.
What is TWST's Compass Score?
Twist Bioscience scores 60/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for TWST?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TWST page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.